News | Ablation Systems | September 15, 2015

Texas Heart Hospital First in United States to Use EpiAccess System

New system offers better visualization of the pericardial cavity during epicardial ablation than traditional fluoroscopic imaging

Texas Cardiac Arrhythmia Institute, TCAI, first in United States, EpiAccess System, epicardial ablation

Image courtesy of EpiEP

September 15, 2015 — The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the United States to use the EpiAccess system to access the pericardial cavity of the heart during an epicardial ablation. The procedure was performed by Andrea Natale, M.D., FHRS, FACC, FESC, cardiac electrophysiologist and executive medical director of TCAI, and J. David Burkhardt, M.D., FACC, cardiac electrophysiologist at TCAI.

The EpiAccess System includes both a single-use needle with an incorporated pressure sensor and a pressure monitor that uses proprietary algorithms to analyze pressure frequency data. Real-time information is presented in an intuitive and easy-to-understand display, which informs physicians of needle tip location to simplify access and to reduce the risk of complications commonly associated with blind sticks.

"The new EpiAccess system may decrease the amount of time it takes to perform these technically challenging procedures and, more importantly, it can increase patient safety and reduce the risk of complications," Natale said. "We are pleased to be among the first facilities in the nation to offer this technology."

Minimally invasive epicardial access is currently performed using fluoroscopic imaging, which can be challenging to use given the difficulty in distinguishing soft tissue features and limitations of two-dimension imaging. Because the pericardial cavity is less than one millimeter thick, the precision of needle placement is critical.

In addition to reducing the risk of complications, such as pericardial effusions, and improving patient outcomes, the EpiAcess System may also reduce the amount of radiation used during these types of procedures.

Access to the pericardial cavity of the heart is necessary when performing complex cardiac ablations and left atrial appendage closures, among other procedures.

For more information: www.tcainstitute.com

Related Content

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati
Medtronic Cobalt and Crome ICD
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received FDA approval for its Cobalt and Crome implantable cardioverter-defibrillators (
The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time. FDA clears, approved, the HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation.

The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time.

News | EP Lab | May 12, 2020
May 12, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the next-generation CardioFocus Inc.
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to edu
The European Heart Rhythm Association (EHRA) electrophysiology (EP) annual meeting cancelled due to coronavirus. #COVID19 #coronavirus #2019nCoV
Feature | EP Lab | March 10, 2020 | Dave Fornell, Editor
March 10, 2020 — Novel coronavirus (...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical SuperMap, an addition to its AcQMap 3-D imaging and mapping system used to guide electrophysiology (EP) catheter ablation procedures. Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in less than three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation, making it practical to execute an iterative "map, ablate, re-map" approach.
News | EP Lab | March 05, 2020
March 5, 2020 — The U.S.